CTSS and severe acute respiratory syndrome: Previous study suggested that camostat, a serine and cysteine protease inhibitor of TMPRSS2, can partially but significantly block SARS-CoV infection, and the combination with alostatin (a cathepsin inhibitor) could significantly enhance the antiviral effect of camostat [21].